| Literature DB >> 24298446 |
Ayaka Ishii-Takahashi1, Ryu Takizawa, Yukika Nishimura, Yuki Kawakubo, Hitoshi Kuwabara, Junko Matsubayashi, Kasumi Hamada, Shiho Okuhata, Noriaki Yahata, Takashi Igarashi, Shingo Kawasaki, Hidenori Yamasue, Nobumasa Kato, Kiyoto Kasai, Yukiko Kano.
Abstract
The differential diagnosis of autism spectrum disorders (ASDs) and attention deficit hyperactivity disorder (ADHD) based solely on symptomatic and behavioral assessments can be difficult, even for experts. Thus, the development of a neuroimaging marker that differentiates ASDs from ADHD would be an important contribution to this field. We assessed the differences in prefrontal activation between adults with ASDs and ADHD using an entirely non-invasive and portable neuroimaging tool, near-infrared spectroscopy. This study included 21 drug-naïve adults with ASDs, 19 drug-naïve adults with ADHD, and 21 healthy subjects matched for age, sex, and IQ. Oxygenated hemoglobin concentration changes in the prefrontal cortex were assessed during a stop signal task and a verbal fluency task. During the stop signal task, compared to the control group, the ASDs group exhibited lower activation in a broad prefrontal area, whereas the ADHD group showed underactivation of the right premotor area, right presupplementary motor area, and bilateral dorsolateral prefrontal cortices. Significant differences were observed in the left ventrolateral prefrontal cortex between the ASDs and ADHD groups during the stop signal task. The leave-one-out cross-validation method using mean oxygenated hemoglobin changes yielded a classification accuracy of 81.4% during inhibitory control. These results were task specific, as the brain activation pattern observed during the verbal fluency task did not differentiate the ASDs and ADHD groups significantly. This study therefore provides evidence of a difference in left ventrolateral prefrontal activation during inhibitory control between adults with ASDs and ADHD. Thus, near-infrared spectroscopy may be useful as an auxiliary tool for the differential diagnosis of such developmental disorders.Entities:
Keywords: Attention deficit hyperactivity disorder; Autism spectrum disorders; Inhibitory control; Near-infrared spectroscopy; Stop signal task
Mesh:
Substances:
Year: 2013 PMID: 24298446 PMCID: PMC3842411 DOI: 10.1016/j.nicl.2013.10.002
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Characteristics and task performance.
| ASDs | ADHD | HC | Comparison | ||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Post-hoc | ||||
| ASDs:HC | ADHD:HC | ASDs:ADHD | |||||
| Age, years | 30.8 (7.2) | 30.6 (7.4) | 28.8 (5.5) | 0.60 | |||
| Sex, men/women | 8 13 | 11 8 | 13 8 | 0.26 | |||
| IQ | 105.1 (14.6) | 102.6 (16.6) | 109.0 (5.6) | 0.25 | |||
| SST (all trials), % | 80.8 (11.6) | 78.9 (13.8) | 84.9 (9.3) | 0.26 | |||
| SST (stop trials), % | 49.2 (38.4) | 56.1 (26.3) | 65.6 (23.6) | 0.22 | |||
| SST (go trials), % | 94.3 (7.2) | 87.7 (20.2) | 92.7 (9.8) | 0.27 | |||
| MRT (SST), ms | 498.0 (102.7) | 539.1 (100.4) | 558.1 (75.8) | 0.11 | |||
| VFT, words | 16.0 (4.3) | 15.5 (4.5) | 16.9 (4.4) | 0.60 | |||
| ASRS | 3.2 (1.8) | 5.2 (0.8) | 1.3 (1.1) | < 0.01 | < 0.01 | < 0.01 | < 0.01 |
| WURS | 53.1 (23.2) | 62.1 (20.0) | 17.5 (9.3) | < 0.01 | < 0.01 | < 0.01 | 0.39 |
| AQ total score | 33.5 (7.9) | 27.6 (5.5) | 13.4 (4.2) | < 0.01 | < 0.01 | < 0.01 | 0.02 |
| GAF | 51.8 (13.2) | 58.8 (10.7) | 84.6 (3.1) | < 0.01 | < 0.01 | < 0.01 | 0.45 |
| Subtype | Asperger, 5; PDD NOS, 16 | ADHD, 11; ADD, 8 | |||||
ASDs, autism spectrum disorders; ADHD, attention deficit hyperactivity disorder; HC, healthy control subjects; Asperger, Asperger syndrome; PDD, pervasive developmental disorder; NOS, pervasive developmental disorder - not otherwise specified; IQ, intelligence quotient; SST, stop signal task; MRT, mean reaction time; VFT, verbal fluency task; ASRS, The World Health Organization (WHO) Adult ADHD Inhibitory-Report Scale; WURS, Wender Utah Rating Scale; AQ, autism spectrum quotient; GAF, Global Assessment of Functioning.
Fig. 1Schematic representation of the stop signal task. Auditory “STOP” signals were given under 3 conditions of delay (ΔT equal to the mean reaction time [MRT], MRT — 100 ms, and MRT — 250 ms) after the “GO” stimulus was presented.
Fig. 2Locations of the near-infrared spectroscopy (NIRS) probes. The locations of NIRS measurements (channels) were estimated probabilistically and labeled anatomically in the standard brain space (LBPA40) according to Tsuzuki et al. (2007).
Fig. 3Time courses of the hemodynamic responses in the left ventrolateral prefrontal cortex (ch50) for the 3 diagnostic groups. The [oxy-Hb] changes for the healthy control (HC) group (black, n = 21), attention deficit hyperactivity disorder (ADHD) group (pink, n = 19), and autism spectrum disorders (ASDs) group (blue, n = 21) during the activation stop signal task (SST) and post-SST conditions are presented as grand-averaged waveforms in ch50. The shaded color indicates the standard deviation.
Fig. 4Differences in [oxy-Hb] changes during the SST between the HC and ADHD groups (A), between the HC and ASDs groups (B), and between the ASDs and ADHD groups (C) (A: post-hoc P ≤ 0.001–0.046; B: post-hoc P = 0.001–0.047: and C: post-hoc P = 0.030–0.034). The colored bar represents the P value.
Fig. 5Differences in [oxy-Hb] changes during the [SST + post-SST] period between the HC and ADHD groups (A), between the HC and ASDs groups (B), and between the ASDs and ADHD groups (C) (A: post-hoc P ≤ 0.001–0.033; B: post-hoc P = 0.005–0.046; and C: post-hoc P = 0.003–0.046). The colored bar represents the P value.
The differences in channels during SST periods.
| Channel | Location | |
|---|---|---|
| ADHD, ASDs < HC | ch2, 3, 11–13, 18, 22, 28, 29, 36, 38, 39, and 46–49 | The frontal pole, both the DLPFC, the right PMA |
| ADHD < HC | ch1–3, 11–13, 18, 22, 28, 29, 36, 38, 39, and 46–49 | The frontal pole, both the DLPFC, the right PMA, and the right pre-SMA |
| ASDs < HC | ch2, 3, 10–13, 18, 20, 22, 24, 28, 29, 31, 32, 35–39, 41, 42, and 45–51 | Both the DLPFC, left VLPFC, left PMA, left pre-SMA and frontal pole |
| Only ADHD < HC | ch1 | The right pre-SMA |
| Only ASDs < HC | ch10, 20, 24, 31, 32, 35, 37, 41, 42, 45, 50, and 51 | Left VLPFC, left PMA, left pre-SMA, and frontal pole |
| ASDs < ADHD | ch50, 51 | Left VLPFC |
| ADHD, ASDs < HC | ch2, 3, 11–13, 18, 22, 28, 29, 36, 38, 39, and 46–49 | The frontal pole, both the DLPFC, the right PMA |
ADHD, attention deficit hyperactivity disorder; ASDs, autism spectrum disorders; DLPFC, dorsolateral prefrontal cortex; PMA, premotor area; pre-SMA, presupplementary motor area; VLPFC, ventrolateral prefrontal cortex.
Differences in channels during [SST + post-SST] periods.
| Channel | Location | |
|---|---|---|
| ADHD, ASDs < HC | ch3, 13, 27, 28, 35, 38, 39, and 46–49 | The frontal pole, bilateral DLPFC, right PMA, and right pre-SMA |
| ADHD < HC | ch3, 13, 27, 28, 35, 38, 39, and 46–49 | The frontal pole, bilateral DLPFC, right PMA, and right pre-SMA |
| ASDs < HC | ch2, 3, 8–10, 12, 13, 18, 20, 24, 26–31, 35–39, 41, 42, and 45–52 | Both DLPFC, both VLPFC, both PMA, both pre-SMA, left temporal, and the frontal pole |
| Only ADHD < HC | None | None |
| Only ASDs < HC | ch2, 8–10, 12, 18, 20, 24, 26, 29, 30, 31, 36, 37, 41, 42, 45, and 50–52 | Left VLPFC, right PMA, left pre-SMA, and frontal pole |
| ASDs < ADHD | ch24, 30, 41, 50, and 51 | Left VLPFC and frontal pole |
ADHD, attention deficit hyperactivity disorder; ASDs, autism spectrum disorders; DLPFC, dorsolateral prefrontal cortex; PMA, premotor area; pre-SMA, presupplementary motor area; VLPFC, ventrolateral prefrontal cortex.
Characteristics and task performance of the secondary groups.
| ASDs with ADHD symptoms | ADHD | HC | Comparison | ||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Post-hoc | ||||
| ASDs:HC | ADHD:HC | ASDs:ADHD | |||||
| Age, years | 29.8 (7.7) | 30.6 (7.4) | 28.8 (5.4) | 0.71 | |||
| Sex, men/women | 6/4 | 11/8 | 8/13 | 0.17 | |||
| IQ | 99.7 (1.6) | 102.6 (16.6) | 109.0 (5.6) | 0.21 | |||
| SST (all trials), % | 78.3 (13.2) | 78.9 (13.8) | 84.9 (9.3) | 0.26 | |||
| SST (stop trials), % | 45.6 (38.4) | 56.1 (26.3) | 65.6 (23.6) | 0.22 | |||
| SST (go trials), % | 92.4 (6.4) | 87.7 (20.2) | 92.7 (9.8) | 0.50 | |||
| MRT (SST), ms | 483.2 (116.6) | 539.1 (100.4) | 558.1 (75.8) | 0.13 | |||
| VFT, words | 13.7 (3.6) | 15.5 (4.5) | 16.9 (4.4) | 0.16 | |||
| ASRS | 4.9 (0.9) | 5.2 (0.8) | 1.3 (1.1) | < 0.01 | < 0.01 | < 0.01 | 0.78 |
| WURS | 61.1 (2.3) | 62.1 (20.0) | 17.5 (9.3) | < 0.01 | < 0.01 | < 0.01 | 0.99 |
| AQ total score | 34.0 (9.8) | 27.6 (5.5) | 13.4 (4.2) | < 0.01 | < 0.01 | < 0.01 | 0.03 |
| GAF | 49.3 (1.4) | 58.8 (10.7) | 84.6 (3.1) | < 0.01 | < 0.01 | < 0.01 | 0.03 |
| Subtype | Asperger, 2; | ADHD, 11; | |||||
| PDD NOS, 8 | ADD, 8 | ||||||
ASDs, autism spectrum disorders; ADHD, attention deficit hyperactivity disorder; HC, healthy control subjects; Asperger, Asperger syndrome; PDD, pervasive developmental disorder; NOS, pervasive developmental disorder – not otherwise specified; IQ, intelligence quotient; SST, stop signal task; MRT, mean reaction time; VFT, verbal fluency task; ASRS, The World Health Organization (WHO) Adult ADHD Inhibitory-Report Scale; WURS, Wender Utah Rating Scale; AQ, autism spectrum quotient; GAF, Global Assessment of Functioning.